Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 22, 2021 - Issue 5
Submit an article Journal homepage
492
Views
2
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?

Emanuel Raschia Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0487-7996View further author information
ORCID Icon,
Gian Paolo Fadinib Cardiology Unit, Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum - University of Bologna, Bologna, ItalyORCID Iconhttps://orcid.org/0000-0002-6510-2097View further author information
ORCID Icon,
Igor Diembergerc Department of Medicine, University of Padova, Padova, ItalyORCID Iconhttps://orcid.org/0000-0002-3823-3809View further author information
ORCID Icon,
Elisabetta Poluzzia Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, ItalyORCID Iconhttps://orcid.org/0000-0002-7209-0426View further author information
ORCID Icon &
Fabrizio De Pontia Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, ItalyORCID Iconhttps://orcid.org/0000-0002-0367-9595View further author information
ORCID Icon
Pages 647-650 | Received 29 Sep 2020, Accepted 02 Nov 2020, Published online: 13 Nov 2020

References

  • Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424.
  • McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
  • American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care. 2020 Jan;43(Suppl 1):S98–S110.
  • Raschi E, Poluzzi E, Marchesini G, et al. Dapagliflozin and cardiovascular outcomes: anything else to DECLARE? Expert Opin Pharmacother. 2019;20(9):1087–1090.
  • Raschi E, Poluzzi E, Fadini GP, et al. Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough? Diabetes Obes Metab. 2018;20(12):2711–2723.
  • McMurray JJ. EMPEROR-Reduced: confirming sodium-glucose cotransporter 2 (SGLT2) inhibitors as an essential treatment for patients with heart failure with reduced ejection fraction [published online ahead of print, 2020 Sep 18]. Eur J Heart Fail. 2020. DOI:10.1002/ejhf.2006
  • Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819-829.
  • Griffin M, Rao VS, Ivey-Miranda J, et al. Empagliflozin in heart failure: diuretic and cardio-renal effects. Circulation. 2020;142(11):1028-1039.
  • Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020 Jul 11;396(10244):121–128.
  • Seferovic JP, Claggett B, Seidelmann SB, et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017 May 5;5:333–340.
  • de la Espriella R, Bayés-Genís A, Morillas H, et al. Renal function dynamics following co-administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes. ESC Heart Fail. 2020 Sep 22. Epub ahead of print. PMID: 32964683. DOI:10.1002/ehf2.12965
  • Fadini GP, Sarangdhar M, De Ponti F, et al. Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors. BMJ Open Diabetes Res Care. 2019 Oct 4;7(1):e000725.
  • Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med. 2004;351(6):543–551.
  • Avogaro A, Fadini GP, Del Prato S. Reinterpreting cardiorenal protection of renal sodium-glucose cotransporter 2 inhibitors via cellular life history programming. Diabetes Care. 2020;43(3):501–507.
  • Colombo G, Casella R, Cazzaniga A, et al. Gruppo di Autoformazione Metodologica (GrAM). Dapagliflozin in patients with heart failure and reduced ejection fraction. Intern Emerg Med. 2020;15(3):515–517.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.